Yahaira Naaldijk, Belén Fernández, Rachel Fasiczka, Elena Fdez, Coline Leghay, Ioana Croitoru, John B Kwok, Yanisse Boulesnane, Amelie Vizeneux, Eugenie Mutez, Camille Calvez, Alain Destée, Jean-Marc Taymans, Ana Vinagre Aragon, Alberto Bergareche Yarza, Shalini Padmanabhan, Mario Delgado, Roy N Alcalay, Zac Chatterton, Nicolas Dzamko, Glenda Halliday, Javier Ruiz-Martínez, Marie-Christine Chartier-Harlin, Sabine Hilfiker
Parkinson´s disease (PD) is a common neurodegenerative movement disorder and leucine-rich repeat kinase 2 (LRRK2) is a promising therapeutic target for disease intervention. However, the ability to stratify patients who will benefit from such treatment modalities based on shared etiology is critical for the success of disease-modifying therapies. Ciliary and centrosomal alterations are commonly associated with pathogenic LRRK2 kinase activity and can be detected in many cell types. We previously found centrosomal deficits in immortalized lymphocytes from G2019S-LRRK2 PD patients...
January 8, 2024: NPJ Parkinson's Disease